You just read:

TAGRISSO™ (osimertinib) approved by Health Canada as treatment for patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer

News provided by

AstraZeneca Canada Inc.

Jul 11, 2016, 07:59 ET